Rev Esp Quimioter 2023; 36(3): 310-313
Epidemiology and prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium in a tertiary hospital from Madrid, Spain
ALFREDO MALDONADO-BARRUECO, MONSERRAT RODRÍGUEZ-AYALA, DAVID GRANDIOSO-VAS, PALOMA GARCÍA-CLEMENTE, GLADYS VIRGINIA GUEDEZ-LÓPEZ, JULIO GARCÍA-RODRÍGUEZ, INMACULADA QUILES-MELERO
Published: 10 March 2023
Objectives. Mycoplasma genitalium causes persistent sexually transmitted infections. The aims of this study were to estimate the prevalence of resistances to macrolides and fluoroquinolones in M. genitalium and the sexually transmitted coinfections in patients at Hospital Universitario La Paz (Madrid, Spain).
Material and methods. Patients attended between January and October 2021 were studied. Screening for sexually transmitted pathogens and detection of 23S rRNA and parC genes mutations were performed by real-time PCR (Allplex,SeegeneTM).
Results. A total of 1,518 females and 1,136 males were studied. The prevalence of M. genitalium was 2.1%. The macrolides resistance rate was 51.8%. The mutations found were A2059G, A2058T and A2058G. The rate of resistance to fluoroquinolones was 17.8% being the G248T mutation (S83I) the most frequent. Seven males had some sexual transmitted coinfection.
Conclusions. Although the percentage of M. genitalium infections is low, the high rate of resistance to macrolides makes it necessary to revise the protocols for diagnosis and empirical treatment of sexually transmitted infections. The use of fluoroquinolones is appropriate after screening of macrolide resistance profile.
Rev Esp Quimioter 2023; 36(3): 310-313 [Full-text PDF]